77 related articles for article (PubMed ID: 22367883)
1. Cervical screening in England: the past, present, and future.
Albrow R; Kitchener H; Gupta N; Desai M
Cancer Cytopathol; 2012 Apr; 120(2):87-96. PubMed ID: 22367883
[TBL] [Abstract][Full Text] [Related]
2. ABC3 Part I: a review of the guidelines for terminology, classification and management of cervical cytology in England.
Smith JH
Cytopathology; 2012 Dec; 23(6):353-9. PubMed ID: 23173804
[TBL] [Abstract][Full Text] [Related]
3. Commentary on "Cervical cancer screening in England: the past, present, and future": a comparison with Canada.
Duggan MA
Cancer Cytopathol; 2012 Apr; 120(2):97-101. PubMed ID: 22367793
[TBL] [Abstract][Full Text] [Related]
4. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
Saraiya M; Irwin KL; Carlin L; Chen X; Jain N; Benard V; Montano DE
Cancer; 2007 Sep; 110(5):1024-32. PubMed ID: 17628488
[TBL] [Abstract][Full Text] [Related]
6. Cancer screening of the uterine cervix papanicolaou smears versus state-of-the-art human papillomavirus testing.
Knight B
Cancer Cytopathol; 2012 Apr; 120(2):105-7. PubMed ID: 22367779
[TBL] [Abstract][Full Text] [Related]
7. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines.
Almonte M; Sasieni P; Cuzick J
Best Pract Res Clin Obstet Gynaecol; 2011 Oct; 25(5):617-29. PubMed ID: 21683657
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus testing for primary cervical cancer screening.
Grce M; Davies P
Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
[TBL] [Abstract][Full Text] [Related]
9. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing.
Sherman ME; Schiffman MH; Lorincz AT; Herrero R; Hutchinson ML; Bratti C; Zahniser D; Morales J; Hildesheim A; Helgesen K; Kelly D; Alfaro M; Mena F; Balmaceda I; Mango L; Greenberg M
Cancer; 1997 Apr; 81(2):89-97. PubMed ID: 9126136
[TBL] [Abstract][Full Text] [Related]
10. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
[TBL] [Abstract][Full Text] [Related]
11. [Can human papillomavirus testing and vaccination prevent cervical cancer?].
Lie AK; Bjørge T; Helland A; Hagen B; Skjeldestad FE; Hagmar B; Thoresen S
Tidsskr Nor Laegeforen; 2001 Oct; 121(25):2947-51. PubMed ID: 11715778
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
14. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience.
Lonky NM; Mahdavi A; Wolde-Tsadik G; Bajamundi K; Felix JC
J Low Genit Tract Dis; 2010 Jul; 14(3):200-5. PubMed ID: 20592555
[TBL] [Abstract][Full Text] [Related]
17. A study of the impact of adding HPV types to cervical cancer screening and triage tests.
Schiffman M; Khan MJ; Solomon D; Herrero R; Wacholder S; Hildesheim A; Rodriguez AC; Bratti MC; Wheeler CM; Burk RD; ;
J Natl Cancer Inst; 2005 Jan; 97(2):147-50. PubMed ID: 15657345
[TBL] [Abstract][Full Text] [Related]
18. Cytology, liquid-based cytology and automation.
Smith JH
Best Pract Res Clin Obstet Gynaecol; 2011 Oct; 25(5):585-96. PubMed ID: 21632286
[TBL] [Abstract][Full Text] [Related]
19. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
20. [Role of cytological test for cervices to identify human papillomavirus in the screening program on serious cervical lesion].
Wang GP; Li RZ; Wu LN; Li J; Liu ZH; Wang C; Zhou YQ; Weng LM; Wu RF
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):626-30. PubMed ID: 19957634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
